Our goal is to understand immune responses to hepatitis C virus and design new vaccines that provoke robust innate and adaptive immune responses to the virus without immune escape. This is an unmet need for a disease that affects over 80 million people globally but with limited and prohibitively expensive treatment options. Our team is highly interdisciplinary with a broad expertise. Clinically, we undertake prospective studies and clinical trials related to hepatitis C infection in prisons. These studies ensure collection of unique clinical samples. Our laboratories apply inter-disciplinary methods that include state-of-the-art molecular, proteomics and cell biology approaches to identify key immune determinants that result in favorable clinical outcome during hepatitis C infection. To this end, we have a unique cohort of patients that are highly resistant to hepatitis C infection, despite high risk exposure. We will characterise their efficient immunity to the virus to inform us in developing vaccines that trigger effective protective immunity.
Back to search results